Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports
Exhibit 99.1 Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial
KT-579 (IRF5) Phase 1 healthy volunteer data demonstrated deep, sustained IRF5 degradation, robust modulation of disease-relevant biomarkers and a favorable safety profile
Last patient completed last visit in KT-621 (STAT6) BROADEN2 Phase 2b AD trial, with topline data to be reported by year-end 2026
KT-621 BREADTH Phase 2b asthma trial ongoing, with topline data expected to be reported in late 2027
Well-capitalized with $1.6 billion in cash as of September 30, 2026, and runway into 2029
Company to hold video conference call and webcast today at 8:30 a.m. ET Watertown, Mass. (October 29, 2026) –Kymera Therapeutics, Inc.(NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today reported financial results for the third quarter ended September 30, 2026, and provided business highlights and updates on its pipeline.
“Kymera’s recent progress reinforces the opportunity across our portfolio and our ability to help shape a new era of differentiated oral medicines in immunology,” said Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics. “With KT-621 and KT-579, we are advancing complementary immunoregulatory mechanisms that target distinct drivers of disease, with significant potential to address unmet needs across the current treatment landscape. The last patient has now completed their week 16 visit in our KT-621 BROADEN2 Phase 2b atopic dermatitis trial, and we plan to report topline data by year-end 2026. We also are planning to initiate our first Phase 3 AD trial by mid-2027, and report data from our BREADTH Phase 2b asthma trial in late 2027.”
Dr. Mainolfi continued, “The positive results from the Phase 1 healthy volunteer trial of KT-579, which we reported today, demonstrate strong translation of its preclinical pharmacology into humans and highlight its potential to modulate multiple core inflammatory pathways through a single oral mechanism. These findings exceed our expectations in terms of depth of degradation, safety and pathway suppression measured by downstream cytokines and gene transcripts. The results provide an important foundation as we advance KT-579, our 7thdegrader to enter the clinic, toward a study in lupus patients and explore the opportunity for targeting IRF5 in additional autoimmune diseases. Beyond these clinical programs, our research engine remains focused on unlocking novel biology and pursuing high value targets to build the next wave of oral medicines for patients who need effective, safe and convenient treatment options.”
KT-621 is an investigational, first-in-class, once daily, oral degrader of STAT6, the specific transcription factor responsible for IL-4/IL-13 signaling and the central driver of Type 2 inflammation. KT-621 is currently in Phase 2 clinical development inatopic dermatitis (AD) and asthma. KT-621 has the potential to transform treatment paradigms by offering a safe, effective, oral option for the more than 140 million patients worldwide living with Type 2 diseases, such as AD, asthma, chronic obstructive pulmonary disease (COPD), eosinophilic esophagitis (EoE), chronic rhinosinusitis with nasal polyps (CRSwNP), chronic spontaneous urticaria (CSU), prurigo nodularis (PN), and bullous pemphigoid (BP), among others.
In October 2026, the last patient received their final dose and completed the week 16 visit in the KT-621 BROADEN2 Phase 2b clinical trial in patients with moderate to severe AD. The Company plans to report topline data by year-end 2026. Subject to discussions with regulators, the Company expects to initiate the first Phase 3 trial in AD by mid-2027.
Enrollment is ongoing in the KT-621 BREADTH Phase 2b clinical trial in patients with moderate to severe eosinophilic asthma, with topline data expected to be reported in late 2027.
In September 2026, the Company presented data from the KT-621 BroADen Phase 1b clinical trial in AD across leading dermatology and respiratory forums, including posters at the European Academy of Dermatology and Venereology (EADV) and European Respiratory Society (ERS) Congresses.
KT-579 is an investigational, first-in-class, oral degrader of IRF5, a genetically validated transcription factor and master regulator of immunity. KT-579 has the potential to modulate multiple core inflammatory pathways through a single oral mechanism, offering a differentiated approach to serious autoimmune diseases where effective and well-tolerated oral therapies are needed, such as lupus, inflammatory bowel disease (IBD), Sjögren's, rheumatoid arthritis (RA) and others.
The Company today announced positive results from the completed first-in-human KT-579 Phase 1 healthy volunteer trial. The results met or exceeded study objectives and established strong proof of mechanism:
Pharmacokinetics and pharmacodynamics: KT-579 demonstrated a favorable plasma pharmacokinetic profile. Exposure increased with dose following single and multiple doses. Robust, sustained IRF5 degradation was observed following a single oral dose in the single ascending dose (SAD) portion of the trial. In the multiple ascending dose portion (MAD), KT-579 demonstrated deep, sustained IRF5 degradation in blood, with ≥90% median degradation across multiple dose levels with saturation of degradation by dose level 3 . Similar reductions in IRF5 levels were also observed in skin, demonstrating target degradation in tissue as well as blood.
Ex vivo-stimulated IRF5-dependent biomarkers: KT-579 showed robust suppression of disease-relevant blood biomarkers and significant downregulation of pathway gene transcripts, reflecting pharmacodynamic effects on the three immune pathways modulated by IRF5 including inflammatory cytokines, interferon (IFN) response, and B-cell biology. The inflammatory cytokine and IFN analysis using the median of all MAD dose cohorts showed inhibition of 88% of TNFα, 87% of IL-12/23p40, 94% of IL-1β, and 98% of IFNβ at Day 14. Gene-expression analyses also showed broad downregulation of inflammatory cytokine, interferon and B-cell associated genes, supporting the functional cytokine findings.
Safety and tolerability: The safety profile of KT-579 was comparable to placebo. There were no serious or severe adverse events (AEs) and no AEs leading to discontinuation. Very few mild treatment-related AEs were reported, and there was no dose-dependent pattern in treatment-emergent AEs. There were no clinically relevant changes in vital signs, laboratory tests or ECGs.
The KT-579 LUMORA Phase 1b trial in lupus patients is planned to start by early 2027. LUMORA is a randomized, double-blind, placebo-controlled trial testing KT-579 in approximately 30 adult patients with systemic lupus erythematosus dosed over 16 weeks. The key aim of this biomarker study is to demonstrate that KT-579 can modulate underlying disease biology with a favorable safety and tolerability profile while exploring potential clinical benefits.
The Company will present new preclinical data on KT-579 in an oral presentation at the American College of Rheumatology (ACR) Convergence conference, taking place November 6-11, 2026, in Orlando, FL. The presentation will highlight KT-579’s compelling profile, including significant activity both as a monotherapy and in combination with background therapies in preclinical lupus models.
The first-in-human Phase 1 clinical trial evaluating KT-485 (SAR447971) in healthy volunteers and hidradenitis suppurativa patients is ongoing. Under the collaboration, Sanofi is leading development, regulatory and commercial efforts for the program. KT-485 is a potent, selective, oral second-generation IRAK4 degrader with the potential to offer a novel approach for a range of chronic immuno-inflammatory diseases.
Gilead Sciences is advancing KT-200 in IND-enabling studies to support an IND filing in 2027. KT-200 is a first-in-class, oral CDK2 molecular glue degrader development candidate discovered and characterized by Kymera and exclusively licensed to Gilead. KT-200 has the potential to improve the standard of care for patients with breast cancer and other solid tumors.
Leveraging its unique target selection strategy, proven small molecule discovery capabilities, and deep development expertise, the Company continues to advance an early pipeline of novel oral programs with a goal to deliver at least one new development candidate per year.
In July 2026, the Company appointed Terence Rooney, MD, as Chief Medical Officer and Elizabeth Laws, PhD, as Senior Vice President, Global STAT6 Development Program Leader, strengthening its clinical development leadership to support the continued advancement of Kymera’s oral immunology portfolio.
Collaboration Revenues:There were no collaboration revenues for the third quarter of 2026 compared to $2.8 million for the third quarter of 2025. Collaboration revenues recognized in the third quarter of 2025 were all attributable to the Company’s collaboration with Gilead. The Company does not expect to recognize additional collaboration revenue in 2026.
Research and Development Expenses:Research and development expenses were $128.5 million for the third quarter of 2026 compared to $74.1 million for the third quarter of 2025. This increase was primarily due to increased expenses related to the investment in the Company’s STAT6 program, platform and discovery programs, as well as costs related to continued growth in the research and development organization. Stock based compensation expenses included in R&D were $10.9 million and $8.4 million for the third quarters of 2026 and 2025, respectively.
General and Administrative Expenses:General and administrative expenses were $18.7 million for the third quarter of 2026 compared to $17.3 million for the third quarter of 2025. The increase was primarily due to an increase in legal and professional service fees in support of the Company’s growth and an increase in personnel, facility, occupancy, and other expenses to support growth as a public company. Stock based compensation expenses included in G&A were $7.9 million and $7.4 million for the third quarters of 2026 and 2025, respectively.
Net Loss:Net loss was $132.0 million for the third quarter of 2026 compared to $82.2 million for the third quarter of 2025.
Cash and Cash Equivalents:As of September 30, 2026, Kymera had $1.6 billion in cash, cash equivalents and investments. Kymera expects that its cash balance will provide the Company with a cash runway into 2029 beyond multiple clinical inflection points in its pipeline.
Kymera will host a video conference call today, October 29, 2026, at 8:30 a.m. ET. To join the call please usethis linkto register. A live webcast of the event will be available underNews and Eventsin the Investors section of the Company’s website atwww.kymeratx.com. A replay of the webcast will be archived and available following the event.
About Kymera TherapeuticsKymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visitwww.kymeratx.comor follow us onXorLinkedIn.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about our expectations regarding strategy, business plans and objectives on the development of our clinical and preclinical pipeline, including the therapeutic potential, clinical benefits and safety thereof, the KT-485/SAR447971 and KT-200 programs, and Kymera’s financial condition and expected cash runway into 2029. The words "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target," “upcoming” and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from any forward-looking statements contained in this press release, including, without limitation, risks associated with: the risk that preclinical and clinical data, including the results from the Phase 1 trials of KT-621 and KT-579, are not predictive of, may be inconsistent with, or more favorable than, data generated from future or ongoing clinical trials of the same product candidate, uncertainties inherent in the initiation, timing and design of future clinical trials, the availability and timing of data from ongoing and future clinical trials and the results of such trials, the ability to successfully demonstrate the safety and efficacy of drug candidates, the timing and outcome of planned interactions with and submissions to regulatory authorities, the availability of funding sufficient for our operating expenses and capital expenditure requirements, the unexpected emergence of adverse events or other undesirable side effects during preclinical and clinical development, and other factors. These risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in the most recent Quarterly Report on Form 10-Q and in subsequent filings with the SEC. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
KYMERA THERAPEUTICS, INC. Consolidated Balance Sheets (In thousands, except share and per share amounts) (Unaudited) September 30, December 31, 2026 2025 Assets Cash, cash equivalents and marketable $ 1,645,883 $ 1,619,434 securities Property and equipment, 38,242 43,175 net Right-of-use assets, 40,444 42,351 operating lease Other assets 42,700 37,852 Total assets $ 1,767,269 $ 1,742,812 Liabilities and Stockholders’ Equity Accrued expenses $ 63,315 $ 42,274 Operating lease 74,626 78,975 liabilities Other liabilities 14,801 41,899 Total liabilities 152,742 163,148 Total stockholders’ 1,614,527 1,579,664 equity Total liabilities, preferred stock and $ 1,767,269 $ 1,742,812 stockholders’ equity
KYMERA THERAPEUTI… INC. Consolidat… Statements of Operations and Comprehens… Loss (In thousands, except share and per share amounts) (Unaudited) Three Months Nine Months Ended Ended September September 30, 30, 2026 2025 2026 2025 Collaborat… $ $ $ $ Revenue — 2,764 99,365 36,341 Operating expenses: Research $ $ $ $ and 128,509 74,094 346,152 232,737 development General and 18,723 17,336 60,207 51,252 administra… Impairment of — 3,855 — 3,855 long-lived assets Total operating 147,232 95,285 406,359 287,844 expenses Loss from -147,232 -92,521 -306,994 -251,503 operations Other income (expense): Interest and other 15,295 10,444 44,753 27,413 income Interest and other -62 -98 -203 -280 expense Total other 15,233 10,346 44,550 27,133 income Net loss attributab… $ $ $ $ to common (131,999) (82,175) (262,444) (224,370) stockholde… Net loss per share attributab… to $ $ $ $ common (1.32) (0.94) (2.66) (2.71) stockholde… basic and diluted Weighted average common stocks 100,097,242 87,300,286 98,612,278 82,653,142 outstandin… basic and diluted
Full text with the tables
Exhibit 99.1
Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports
Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial
KT-579 (IRF5) Phase 1 healthy volunteer data demonstrated deep, sustained IRF5
degradation, robust modulation of disease-relevant biomarkers and a favorable
safety profile
KT-579 LUMORA Phase 1b trial in lupus patients planned to start by early 2027
Last patient completed last visit in KT-621 (STAT6) BROADEN2 Phase 2b AD trial,
with topline data to be reported by year-end 2026
KT-621 BREADTH Phase 2b asthma trial ongoing, with topline data expected to be
reported in late 2027
Well-capitalized with $1.6 billion in cash as of September 30, 2026, and runway
into 2029
Company to hold video conference call and webcast today at 8:30 a.m. ET
Watertown, Mass. (October 29, 2026) –Kymera Therapeutics, Inc.(NASDAQ: KYMR), a
clinical-stage biopharmaceutical company advancing a new class of oral small
molecule degrader medicines for immunological diseases, today reported financial
results for the third quarter ended September 30, 2026, and provided business
highlights and updates on its pipeline.
“Kymera’s recent progress reinforces the opportunity across our portfolio and
our ability to help shape a new era of differentiated oral medicines in
immunology,” said Nello Mainolfi, PhD, Founder, President and CEO, Kymera
Therapeutics. “With KT-621 and KT-579, we are advancing complementary
immunoregulatory mechanisms that target distinct drivers of disease, with
significant potential to address unmet needs across the current treatment
landscape. The last patient has now completed their week 16 visit in our KT-621
BROADEN2 Phase 2b atopic dermatitis trial, and we plan to report topline data by
year-end 2026. We also are planning to initiate our first Phase 3 AD trial by
mid-2027, and report data from our BREADTH Phase 2b asthma trial in late 2027.”
Dr. Mainolfi continued, “The positive results from the Phase 1 healthy volunteer
trial of KT-579, which we reported today, demonstrate strong translation of its
preclinical pharmacology into humans and highlight its potential to modulate
multiple core inflammatory pathways through a single oral mechanism. These
findings exceed our expectations in terms of depth of degradation, safety and
pathway suppression measured by downstream cytokines and gene transcripts. The
results provide an important foundation as we advance KT-579, our 7thdegrader to
enter the clinic, toward a study in lupus patients and explore the opportunity
for targeting IRF5 in additional autoimmune diseases. Beyond these clinical
programs, our research engine remains focused on unlocking novel biology and
pursuing high value targets to build the next wave of oral medicines for
patients who need effective, safe and convenient treatment options.”
Business Highlights, Recent Developments and Upcoming Milestones
STAT6 Degrader Program
KT-621 is an investigational, first-in-class, once daily, oral degrader of
STAT6, the specific transcription factor responsible for IL-4/IL-13 signaling
and the central driver of Type 2 inflammation. KT-621 is currently in Phase 2
clinical development inatopic dermatitis (AD) and asthma. KT-621 has the
potential to transform treatment paradigms by offering a safe, effective, oral
option for the more than 140 million patients worldwide living with Type 2
diseases, such as AD, asthma, chronic obstructive pulmonary disease (COPD),
eosinophilic esophagitis (EoE), chronic rhinosinusitis with nasal polyps
(CRSwNP), chronic spontaneous urticaria (CSU), prurigo nodularis (PN), and
bullous pemphigoid (BP), among others.
In October 2026, the last patient received their final dose and completed the
week 16 visit in the KT-621 BROADEN2 Phase 2b clinical trial in patients with
moderate to severe AD. The Company plans to report topline data by year-end
2026. Subject to discussions with regulators, the Company expects to initiate
the first Phase 3 trial in AD by mid-2027.
Enrollment is ongoing in the KT-621 BREADTH Phase 2b clinical trial in patients
with moderate to severe eosinophilic asthma, with topline data expected to be
reported in late 2027.
In September 2026, the Company presented data from the KT-621 BroADen Phase 1b
clinical trial in AD across leading dermatology and respiratory forums,
including posters at the European Academy of Dermatology and Venereology (EADV)
and European Respiratory Society (ERS) Congresses.
IRF5 Degrader Program
KT-579 is an investigational, first-in-class, oral degrader of IRF5, a
genetically validated transcription factor and master regulator of immunity.
KT-579 has the potential to modulate multiple core inflammatory pathways through
a single oral mechanism, offering a differentiated approach to serious
autoimmune diseases where effective and well-tolerated oral therapies are
needed, such as lupus, inflammatory bowel disease (IBD), Sjögren's, rheumatoid
arthritis (RA) and others.
The Company today announced positive results from the completed first-in-human
KT-579 Phase 1 healthy volunteer trial. The results met or exceeded study
objectives and established strong proof of mechanism:
Pharmacokinetics and pharmacodynamics: KT-579 demonstrated a favorable plasma
pharmacokinetic profile. Exposure increased with dose following single and
multiple doses. Robust, sustained IRF5 degradation was observed following a
single oral dose in the single ascending dose (SAD) portion of the trial. In the
multiple ascending dose portion (MAD), KT-579 demonstrated deep, sustained IRF5
degradation in blood, with ≥90% median degradation across multiple dose levels
with saturation of degradation by dose level 3 . Similar reductions in IRF5
levels were also observed in skin, demonstrating target degradation in tissue as
well as blood.
Ex vivo-stimulated IRF5-dependent biomarkers: KT-579 showed robust suppression
of disease-relevant blood biomarkers and significant downregulation of pathway
gene transcripts, reflecting pharmacodynamic effects on the three immune
pathways modulated by IRF5 including inflammatory cytokines, interferon (IFN)
response, and B-cell biology. The inflammatory cytokine and IFN analysis using
the median of all MAD dose cohorts showed inhibition of 88% of TNFα, 87% of
IL-12/23p40, 94% of IL-1β, and 98% of IFNβ at Day 14. Gene-expression analyses
also showed broad downregulation of inflammatory cytokine, interferon and B-cell
associated genes, supporting the functional cytokine findings.
Safety and tolerability: The safety profile of KT-579 was comparable to placebo.
There were no serious or severe adverse events (AEs) and no AEs leading to
discontinuation. Very few mild treatment-related AEs were reported, and there
was no dose-dependent pattern in treatment-emergent AEs. There were no
clinically relevant changes in vital signs, laboratory tests or ECGs.
The KT-579 LUMORA Phase 1b trial in lupus patients is planned to start by early
2027. LUMORA is a randomized, double-blind, placebo-controlled trial testing
KT-579 in approximately 30 adult patients with systemic lupus erythematosus
dosed over 16 weeks. The key aim of this biomarker study is to demonstrate that
KT-579 can modulate underlying disease biology with a favorable safety and
tolerability profile while exploring potential clinical benefits.
The Company will present new preclinical data on KT-579 in an oral presentation
at the American College of Rheumatology (ACR) Convergence conference, taking
place November 6-11, 2026, in Orlando, FL. The presentation will highlight
KT-579’s compelling profile, including significant activity both as a
monotherapy and in combination with background therapies in preclinical lupus
models.
Partnered Programs & Research
The first-in-human Phase 1 clinical trial evaluating KT-485 (SAR447971) in
healthy volunteers and hidradenitis suppurativa patients is ongoing. Under the
collaboration, Sanofi is leading development, regulatory and commercial efforts
for the program. KT-485 is a potent, selective, oral second-generation IRAK4
degrader with the potential to offer a novel approach for a range of chronic
immuno-inflammatory diseases.
Gilead Sciences is advancing KT-200 in IND-enabling studies to support an IND
filing in 2027. KT-200 is a first-in-class, oral CDK2 molecular glue degrader
development candidate discovered and characterized by Kymera and exclusively
licensed to Gilead. KT-200 has the potential to improve the standard of care for
patients with breast cancer and other solid tumors.
Leveraging its unique target selection strategy, proven small molecule discovery
capabilities, and deep development expertise, the Company continues to advance
an early pipeline of novel oral programs with a goal to deliver at least one new
development candidate per year.
Corporate
In July 2026, the Company appointed Terence Rooney, MD, as Chief Medical Officer
and Elizabeth Laws, PhD, as Senior Vice President, Global STAT6 Development
Program Leader, strengthening its clinical development leadership to support the
continued advancement of Kymera’s oral immunology portfolio.
Financial Results
Collaboration Revenues:There were no collaboration revenues for the third
quarter of 2026 compared to $2.8 million for the third quarter of 2025.
Collaboration revenues recognized in the third quarter of 2025 were all
attributable to the Company’s collaboration with Gilead. The Company does not
expect to recognize additional collaboration revenue in 2026.
Research and Development Expenses:Research and development expenses were $128.5
million for the third quarter of 2026 compared to $74.1 million for the third
quarter of 2025. This increase was primarily due to increased expenses related
to the investment in the Company’s STAT6 program, platform and discovery
programs, as well as costs related to continued growth in the research and
development organization. Stock based compensation expenses included in R&D were
$10.9 million and $8.4 million for the third quarters of 2026 and 2025,
respectively.
General and Administrative Expenses:General and administrative expenses were
$18.7 million for the third quarter of 2026 compared to $17.3 million for the
third quarter of 2025. The increase was primarily due to an increase in legal
and professional service fees in support of the Company’s growth and an increase
in personnel, facility, occupancy, and other expenses to support growth as a
public company. Stock based compensation expenses included in G&A were $7.9
million and $7.4 million for the third quarters of 2026 and 2025, respectively.
Net Loss:Net loss was $132.0 million for the third quarter of 2026 compared to
$82.2 million for the third quarter of 2025.
Cash and Cash Equivalents:As of September 30, 2026, Kymera had $1.6 billion in
cash, cash equivalents and investments. Kymera expects that its cash balance
will provide the Company with a cash runway into 2029 beyond multiple clinical
inflection points in its pipeline.
Event Details
Kymera will host a video conference call today, October 29, 2026, at 8:30 a.m.
ET. To join the call please usethis linkto register. A live webcast of the event
will be available underNews and Eventsin the Investors section of the Company’s
website atwww.kymeratx.com. A replay of the webcast will be archived and
available following the event.
About Kymera TherapeuticsKymera is a clinical-stage biotechnology company
pioneering the field of targeted protein degradation (TPD) to develop medicines
that address critical health problems and have the potential to dramatically
improve patients’ lives. Kymera is deploying TPD to address disease targets and
pathways inaccessible with conventional therapeutics. Having advanced the first
degrader into the clinic for immunological diseases, Kymera is focused on
building an industry-leading pipeline of oral small molecule degraders to
provide a new generation of convenient, highly effective therapies for patients
with these conditions. Founded in 2016, Kymera has been recognized as one of
Boston’s top workplaces for the past several years. For more information about
our science, pipeline and people, please visitwww.kymeratx.comor follow us
onXorLinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, as amended, including, without
limitation, implied and express statements about our expectations regarding
strategy, business plans and objectives on the development of our clinical and
preclinical pipeline, including the therapeutic potential, clinical benefits and
safety thereof, the KT-485/SAR447971 and KT-200 programs, and Kymera’s financial
condition and expected cash runway into 2029. The words "may," "might," "will,"
"could," "would," "should," "expect," "plan," "anticipate," "intend," "believe,"
"estimate," "seek," "predict," "future," "project," "potential," "continue,"
"target," “upcoming” and similar words or expressions are intended to identify
forward-looking statements, although not all forward-looking statements contain
these identifying words. Any forward-looking statements in this press release
are based on management's current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause actual
events or results to differ materially from any forward-looking statements
contained in this press release, including, without limitation, risks associated
with: the risk that preclinical and clinical data, including the results from
the Phase 1 trials of KT-621 and KT-579, are not predictive of, may be
inconsistent with, or more favorable than, data generated from future or ongoing
clinical trials of the same product candidate, uncertainties inherent in the
initiation, timing and design of future clinical trials, the availability and
timing of data from ongoing and future clinical trials and the results of such
trials, the ability to successfully demonstrate the safety and efficacy of drug
candidates, the timing and outcome of planned interactions with and submissions
to regulatory authorities, the availability of funding sufficient for our
operating expenses and capital expenditure requirements, the unexpected
emergence of adverse events or other undesirable side effects during preclinical
and clinical development, and other factors. These risks and uncertainties are
described in greater detail in the section entitled "Risk Factors" in the most
recent Quarterly Report on Form 10-Q and in subsequent filings with the SEC. In
addition, any forward-looking statements represent our views only as of today
and should not be relied upon as representing our views as of any subsequent
date. We explicitly disclaim any obligation to update any forward-looking
statements. No representations or warranties (expressed or implied) are made
about the accuracy of any such forward-looking statements.
KYMERA THERAPEUTICS,
INC.
Consolidated Balance
Sheets
(In thousands, except
share and per
share amounts)
(Unaudited)
September 30, December 31,
2026 2025
Assets
Cash, cash equivalents
and marketable $ 1,645,883 $ 1,619,434
securities
Property and equipment, 38,242 43,175
net
Right-of-use assets, 40,444 42,351
operating lease
Other assets 42,700 37,852
Total assets $ 1,767,269 $ 1,742,812
Liabilities and
Stockholders’ Equity
Accrued expenses $ 63,315 $ 42,274
Operating lease 74,626 78,975
liabilities
Other liabilities 14,801 41,899
Total liabilities 152,742 163,148
Total stockholders’ 1,614,527 1,579,664
equity
Total liabilities,
preferred stock and $ 1,767,269 $ 1,742,812
stockholders’ equity
KYMERA
THERAPEUTI…
INC.
Consolidat…
Statements
of
Operations
and
Comprehens…
Loss
(In
thousands,
except
share and
per
share
amounts)
(Unaudited)
Three Months Nine Months
Ended Ended
September September
30, 30,
2026 2025 2026 2025
Collaborat… $ $ $ $
Revenue — 2,764 99,365 36,341
Operating
expenses:
Research $ $ $ $
and 128,509 74,094 346,152 232,737
development
General and 18,723 17,336 60,207 51,252
administra…
Impairment
of — 3,855 — 3,855
long-lived
assets
Total
operating 147,232 95,285 406,359 287,844
expenses
Loss from -147,232 -92,521 -306,994 -251,503
operations
Other
income
(expense):
Interest
and other 15,295 10,444 44,753 27,413
income
Interest
and other -62 -98 -203 -280
expense
Total other 15,233 10,346 44,550 27,133
income
Net loss
attributab… $ $ $ $
to common (131,999) (82,175) (262,444) (224,370)
stockholde…
Net loss
per share
attributab…
to $ $ $ $
common (1.32) (0.94) (2.66) (2.71)
stockholde…
basic and
diluted
Weighted
average
common
stocks 100,097,242 87,300,286 98,612,278 82,653,142
outstandin…
basic and
diluted
Investor Contact:
Justine Koenigsberg
[email protected]
857-285-5300
Media Contact:
Matthew Henson
[email protected]
857-285-5300